Neolys Diagnostics

Neolys Diagnostics is a private, pre-revenue diagnostics company focused on personalized radiotherapy in oncology. Its core technology leverages over a decade of academic research, primarily from INSERM in Lyon, to create predictive tests that measure a patient's individual radiosensitivity via ATM protein analysis in blood or tissue samples. This aims to help clinicians optimize radiation dosing, improving efficacy and reducing toxicity. The company is in the development and clinical validation stage, building partnerships across Europe.

Predictive diagnostic tests based on the analysis of the ATM protein's role in DNA damage repair to measure individual patient radiosensitivity for personalized radiotherapy.

The competitive landscape for predictive radiosensitivity tests is nascent but evolving. Competition includes academic research groups publishing on various biomarkers (genomic, cellular) and a few early-stage companies. Neolys's differentiation lies in its specific focus on the functional ATM protein assay and its strong academic collaboration, but it must move quickly to establish clinical validation and IP leadership.